Bortezomib and Bevacizumab (BB-mib-mab) in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)
Sponsor: University of Southern California
A PHASE1/PHASE2 clinical study on Renal Cell Cancer, this trial is ongoing. The trial is conducted by University of Southern California and has accumulated 8 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE1_PHASE2
-
May 2019 — Jan 2021 [monthly]
Unknown Status PHASE1_PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — May 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 3 earlier versions
-
May 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
First recorded
Aug 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Southern California
For direct contact, visit the study record on ClinicalTrials.gov .